Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Phibro Animal Health (PAHC)

Phibro Animal Health Q1 net sales rise 6% to $386.8 million; guidance maintained

Positive Impact 3 of 5 earnings

Phibro Animal Health reported higher first-quarter results for the period ended September 30, 2026, with net sales up 6% and net income up 11% from a year earlier. The company kept its fiscal 2027 guidance unchanged, and stockholders re-elected three Class I directors and ratified PricewaterhouseCoopers as auditor at the November 3, 2026 annual meeting.

Key points

  • Net sales of $386.8 million rose $22.9 million, or 6%, led by Mineral Nutrition, which rose 17%.
  • Net income of $29.5 million rose 11%, and diluted EPS of $0.72 rose $0.07 from $0.65.
  • Fiscal 2027 guidance was maintained: net sales of $1.55 billion to $1.60 billion and adjusted EBITDA of $258 million to $268 million.
  • At the November 3, 2026 annual meeting, all three director nominees were elected and PwC was ratified for the fiscal year ending June 30, 2027.

The filing

CompanyPhibro Animal Health (PAHC)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:31 PM ET
Accession number0001104659-26-122727

Items reported: 2.02 Results of Operations5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.